Steffen N. Email & Phone Number

København, Region Hovedstaden, Danmark

Copenhagen, Capital Region Of Denmark, Denmark

• Responsible for new product opportunities
• Responsible for new technology platforms
• Problem-solver for CSO on critical issues

Copenhagen, Capital Region Of Denmark, Denmark

• Responsible for new product leads in oncology, rare endocrinology and opthalmology.
• End-to-end analysis incl. unmet medical need, disease biology, market opportunity, clinical and preclinical data, competitive space, IP & FTO, pricing, manufacturability.
• Responsible for competitive intelligence and conference debrief within oncology.
• Investor relations (oncology).
• Onboarding of R&D to new projects.

Malmö, Skane County, Sweden

• Head of R&D with focus on inflammatory and autoimmune diseases including RA, IBD, SLE and complement biology. Responsibilities include:
• Pipeline responsible for SVAR R&D incl. feasibility, strategic positioning and delivery of commercial assays for complement (WIESLAB), gene therapy, inflammation & disease biomarkers.
• Corporate strategy relating to synergies between bioanalysis and R&D as well as future research focus.
• Staff management
• BD&L, FTO, competitive environment analysis in gene therapy space and complement biology.
• Patent writing and submission

Denmark

• Biology and project lead on novel drug towards Parkinson’s disease.

Copenhagen Area, Capital Region, Denmark

• Design and implementation of potency assay to support LU AF82422 phase 1 clinical trial.
• Due diligence assessment on +10 business development opportunities covering pre-clinical to late stage assets and CPT and FT member on several projects.
• Co-driver of early activities within translational models to support transition from non-clinical to clinical research.
• Stakeholder management and biological support both internally and externally including academic collaborations within neuroinflammation.

Copenhagen Area, Capital Region, Denmark

• Neurodegeneration scientist with primary focus within Parkinson's disease.
• Determined MoA of antibody based drug in vitro.
• Development of target engagement and biomarker assay.
• Production and QC of antigen.
• Validation of transcytosis of antibody fusion molecules across the BBB (in vitro).Other responsibilities:
• Selection and coordination of CRO/service/purchasing contracts to support non-clinical research.

Toronto, Canada Area

Post doctorate in the lab of Prof. Sergio Grinstein at the Sick Kids Hospital.Primary focus on scavenger receptors and their involvement in cardiac disease and lipid metabolism. The HDL receptor SRB1 was described both mechanistically on a molecular level and in a cellular context using cutting edge techniques (super resolution, single particle tracking.

• Post doc assisting the principal investigator on three projects in academia and with industrial partners. Work function included presenting to stake holders, establishing a peptidomics platform including the IT.
• Project planning and meeting organizer with industrial collaborators.
• Supervision of technicians and Ph.D. students.
• Built and maintained MS server and created custom databases and digestions for several projects.
• Construction of educational website with tutorials.
• Modernization of machine park infrastructure.

Aarhus

• Lactadherin (MFG-E8) is a multifunctional, bioactive protein expressed by macrophages, microglia, mammory gland cells a.o. The bioactive effects stem from an integrin binding RGD site as well as two "C" domains highly.
• Successfully constructed and utilized assays for monitoring enzymatic activity, enterocyte migration and protein bioavailability.
• Determined the bioactive effect of lactadherin on inflammatory phospholipases and wounded, primary cell monolayers.
• Established in-house SOP and taught new users.
• Mentored grad students and taught more than 600 undergrad students and was highest ranked instructor in 3 of 4 anonymous reviews.

Aarhus

• Major in human biology and diseases. Thesis title: "Discovery of the reptilian Na+/H+ transporter (isoform 1): A homeostasis conundrum."When cells are exposed to higher than normal salt they shrink. As shrinking causes.
• Determined the existence of NHE1 in reptiles and close relatives.
• Obtained sequence by PCR and performed phylogenetic comparison.
• Acquired conclusive image based and WB evidence of the presumed missing reptilian NHE1 antiporter.
• Revised the practical lab exercises and taught undergrads.

Aarhus

B.Sc. thesis in the phylogenetic evolution of Na/H antiporters (NHE1) and the missing regulatory volume increase in reptilian red blood cells (RBC). During my B.Sc. I showed that NHE1 is in fact expressed in reptiles, but lacking in RBC's.

Harvard Medical School Under Dr. Gary E. Gilbert At Haematology R&D, VA Boston

• Determination of the efficacy of lactadherin as a novel phospholipase A2 inhibitor. Secreted phospholipases are one of the factors driving inflammation in autoimmune diseases like arthritis, IBD and cardiovascular.
• Determined the efficacy of lactadherin as anti-inflammatory biologic for potential use in autoimmunity.
• Used chromogenic prothrombinase assay to determine PS exposure in cells and liposomes.
• Established an assay to monitor inflammatory phospholipase activity on artificial and live membranes.Skills acquired:
• Spectrofluorometry
• Flow cytometry

Ph.D.

M.Sc.

Upper Secondary School Diploma